Natural Capsules Ltd.
Snapshot View

165.75 -7.75 ▼-4.5%

23 July 2021, 04:00:00 P.M.
Volume: 15,442

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.naturalcapsules.com
Financial Indicators
Market Cap 103.31 Cr.
Earnings per share (EPS) 11.09 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 14.95 Trailing Twelve Months Ending 2021-03
Industry PE 35.17 Trailing Twelve Months Ending 2021-03
Book Value / Share 99.63 Trailing Twelve Months Ending 2021-03
Price to Book Value 1.66 Calculated using Price: 165.75
Dividend Yield 0.60 Period Ending 2021-03
No. of Shares Subscribed 0.62 Cr. 6,232,700 Shares
FaceValue 10
Company Profile

Natural Capsules is a public limited company established in the year 1993.The company is a well-equipped modern manufacturing plant to manufacture hard gelatin capsule shells, Hard cellulose capsule shells and pharmaceutical dosage forms in capsule dosage form.   

The company meets the statutory requirements as laid down by the authorities in respect to cGMP and cGLP practices. Since its inception, Natural Capsules has ensured to provide turnkey solutions to all its customers. NCL has evolved and strengthened its endeavors by constantly innovating through its excellent products. With a mission to enable ‘Technology Assisted Business Transformation’, NCL ensure to deliver the best products with a technological edge.       

The main objective of the company is to manufacture and market hard gelatin capsule shells and hard cellulose capsule shells (both printed and unprinted). These capsules are sold in the domestic market and also exported to several countries. The logical integration of NCL hard shell manufacturing to formulation was initiated in the year 1998.  

The company is also engaged in formulating the pharmaceutical dosage forms in capsule dosage form, both pharma and neutraceutical products. The company is fully committed to upgrade its facilities on a continuous basis to meet the requirements of national and international standards, cGMP and cGLP practices. Natural Capsule has been serving the pharmaceutical industry over a decade, comprising of two units – one at Bangalore and other at Pondicherry.  

The pharmaceutical and dietary supplement industries count on Natural Capsules to supply hard two-piece gelatin and cellulose capsules. With manufacturing sites at Bangalore and Pondicherry, they are serving customers on quick service no matter where they are located. For the past 12 years, with the greatest respect to the customers, Natural Capsules has dedicated itself to the production of the highest quality capsules.

Products and services offered by the company:

Products:

  • Hard Gelatin Capsule Shells
  • Hard Cellulose Capsule Shells
  • BSE / TSE Free Gelatin Capsule Shells
  • Shiny Gelatin Capsule Shells  
  • SLS Free Gelatin Capsule Shells
  • Halal Certified Gelatin Capsule Shells
  • Fortified Gelatin Capsule Shells
  • Sweet Gelatin Capsule Shells
  • Fast Release Gelatin Capsule Shells
  • Printed Gelatin / Cellulose Capsule Shells

Services:    

  • Contract research in synthetic chemistry
  • Dosage development
  • Dossier in CTD format
  • Manufacturing of APIs and finished dosage forms
  • Development of dossiers/ ANDAs for products of the customer’s choice
  • Contract research and analytical 

Achievements/ recognition:

  •  An ISO 9001:2000 cerified company

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-4.47%
1 Week
-5.10%
1 Month
+11.09%
3 Month
+19.16%
6 Month
+79.00%
1 Year
+251.17%
2 Year
+217.22%
5 Year
+61.94%
4 years 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) 2.05 3.50 1.54 11.74
Return on Capital Employed (%) 3.71 4.51 3.71 14.52
Return on Assets (%) 1.56 2.66 1.16 8.05

Balance Sheet View Details

Particulars 4 years 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Shh. Funds 54 55 56 62
Non Curr. Liab. 2 1 1 1
Curr. Liab. 15 16 18 34
Minority Int.
Equity & Liab. 71 73 75 97
Non Curr. Assets 29 35 37 55
Curr. Assets 42 38 38 42
Misc. Exp. not W/O
Total Assets 71 73 75 97

Profit Loss View Details

Particulars 4 years 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Net Sales 55 60 62 80
Other Income 1 1 1 1
Total Income 56 61 63 80
Total Expenditure -49 -55 -56 -68
PBIDT 6 6 6 12
Interest 0 -1 -1 -1
Depreciation -4 -3 -4 -4
Taxation -1 0 -1 -2
Exceptional Items 0 2
PAT 1 2 1 7

Cash Flow View Details

Particulars 4 years 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 5 2 7 13
Cash Fr. Inv. -1 -7 -6 -16
Cash Fr. Finan. -4 4 -1 3
Net Change 0 -1 0 0
Cash & Cash Eqvt 1 0 0 0

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 52.17 52.17 52.17 52.17 52.17 52.17 54.37 54.37 54.37
Public 47.83 47.83 47.83 47.83 47.83 47.83 45.63 45.63 45.63
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Sat, 17 Jul 2021
Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations 2015)
Natural Capsules Ltd has informed BSE regarding the details of Voting results of AGM under Regulation 44(3) of SEBI (LODR) Regulations 2015. Kindly Click here
Fri, 16 Jul 2021
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Declaration of Voting Results & Scrutinizers Report of 28th Annual General Meeting of the Company held on Thursday 15th July 2021.
Thu, 15 Jul 2021
Outcome Of Board Meeting
Outcome of Board Meeting.

Technical Scans View Details

Fri, 23 Jul 2021
Strongly Outperforming Benchmark Index Strongly Outperforming Benchmark Index
Strongly Outperforming Sectoral Index Strongly Outperforming Sectoral Index
Close Within 2 Year High Zone Close Within 2 Year High Zone
Close Within 5 Year High Zone Close Within 5 Year High Zone
Both SRS And ARS Above Zero Both SRS And ARS Above Zero

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 166,513.85 694.00 +1.0%
Divi's Laboratories Ltd. 128,088.59 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. 90,175.51 5,420.50 +0.7%
Cipla Ltd. 76,510.04 948.50 -0.1%
Cadila Healthcare Ltd. 62,965.29 615.05 -0.9%
Aurobindo Pharma Ltd. 56,484.48 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. 56,291.69 3,915.00 -1.8%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 57.34 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2021-03 64.55 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 46.21 5,420.50 +0.7%
Cipla Ltd. Consolidated 2021-03 31.81 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 29.51 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.59 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 374.38 3,915.00 -1.8%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.58 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2021-03 13.78 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 5.15 5,420.50 +0.7%
Cipla Ltd. Consolidated 2021-03 4.17 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 4.85 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.58 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.25 3,915.00 -1.8%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 0.18 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 3,915.00 -1.8%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 10.09 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 3,915.00 -1.8%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 12.53 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 3,915.00 -1.8%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 17,131.99 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 3,915.00 -1.8%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 1,546.98 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 3,915.00 -1.8%